GLPG vs. VKTX, ITCI, JAZZ, BPMC, IONS, OGN, BBIO, CYTK, APLS, and MDGL
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
Viking Therapeutics received 133 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Viking Therapeutics presently has a consensus target price of $112.38, indicating a potential upside of 71.93%. Galapagos has a consensus target price of $34.50, indicating a potential upside of 26.88%. Given Galapagos' stronger consensus rating and higher possible upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Galapagos.
Galapagos has higher revenue and earnings than Viking Therapeutics.
Viking Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
In the previous week, Viking Therapeutics had 8 more articles in the media than Galapagos. MarketBeat recorded 13 mentions for Viking Therapeutics and 5 mentions for Galapagos. Galapagos' average media sentiment score of 1.06 beat Viking Therapeutics' score of 0.26 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -26.25%. Viking Therapeutics' return on equity of -2.60% beat Galapagos' return on equity.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Viking Therapeutics beats Galapagos on 12 of the 16 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
